Rituximab, Mycophenolate Mofetil Compared for Pemphigus Vulgaris
WEDNESDAY, May 19, 2021 -- For patients with pemphigus vulgaris, rituximab is superior to mycophenolate mofetil for producing sustained complete remission at 52 weeks, according to a study published online May 19 in the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 19, 2021 Category: Pharmaceuticals Source Type: news
Antibiotic Cut ANCA-Vasculitis Infection Risk With Rituximab Antibiotic Cut ANCA-Vasculitis Infection Risk With Rituximab
Co-use of cotrimoxazole decreased the risk for infection, which remains high in patients with vasculitis who are treated with rituximab.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 7, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Rituximab Benefits Seen in Neuropsychiatric Lupus Rituximab Benefits Seen in Neuropsychiatric Lupus
Additionally, the use of concomitant cyclophosphamide might enhance the level of improvement seen in some patients, said Dr Trixy David in presenting data at the British Society for Rheumatology meeting.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - April 30, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news
Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Bas ed on this positive CHMP recommendation, a final decision regarding the approval of Venclyxto in certain patients with untreated AML is expected from the European Commission in the near future.“Today’s recommendation...
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news
Increased Risk for Infections in Children With Use of Rituximamb Increased Risk for Infections in Children With Use of Rituximamb
"Our study highlights a role for heightened vigilance of rituximab-associated hypogammaglobulinemia and infections in pediatric patients with rheumatic conditions," investigators concluded.Medscape Medical News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - April 20, 2021 Category: Pediatrics Tags: Rheumatology News Source Type: news
Vaccines Won ’t Protect Millions of Patients With Weakened Immune Systems
Many cannot produce enough infection-fighting cells to fend off the coronavirus. But researchers are testing one therapy that may help: monoclonal antibodies. (Source: NYT Health)
Source: NYT Health - April 16, 2021 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Antibodies Coronavirus (2019-nCoV) Vaccination and Immunization Immune System Drugs (Pharmaceuticals) Autoimmune Diseases Rituxan Leukemia & Lymphoma Society Regeneron Pharmaceuticals Inc Source Type: news
AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma
Significant reduction found in risk for disease progression/death for C+R versus placebo and rituximab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 13, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news
Combo Provides'Broad Benefit' Across NHL Subtypes Combo Provides'Broad Benefit' Across NHL Subtypes
The combination of copanlisib + rituximab led to a reduction in the risk for disease progression/death when compared with rituximab + placebo in patients with relapsed, indolent non-Hodgkin lymphoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma
TUESDAY, April 13, 2021 -- Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
● Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
● Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news
Combination-copanlisib-rituximab-significantly-increases-progression-free-survival-patients-relapsed
Copanlisib is the first and only PI3K inhibitor to demonstrate broad and superior efficacy in combination with rituximab in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) compared to rituximab and placebo / Phase III trial CHRONOS-3 showed the combination of copanlisib and rituximab resulted in a 48% reduction in the risk of disease progression or death in patients with iNHL / The strong reduction in risk of progression or death was observed across all prespecified iNHL subtypes / The adverse event (AE) profile of the copanlisib and rituximab combination was manageable and generally consistent with pre...
Source: Bayer Company News - April 10, 2021 Category: Pharmaceuticals Source Type: news
Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 9, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Riabni (Rituximab-arrx Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 13, 2021 Category: Drugs & Pharmacology Source Type: news
FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan
THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Riabni (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 17, 2020 Category: Drugs & Pharmacology Source Type: news
